JP2022515770A5 - - Google Patents
Info
- Publication number
- JP2022515770A5 JP2022515770A5 JP2021535950A JP2021535950A JP2022515770A5 JP 2022515770 A5 JP2022515770 A5 JP 2022515770A5 JP 2021535950 A JP2021535950 A JP 2021535950A JP 2021535950 A JP2021535950 A JP 2021535950A JP 2022515770 A5 JP2022515770 A5 JP 2022515770A5
- Authority
- JP
- Japan
- Prior art keywords
- bispecific antibody
- heavy chain
- domain
- seq
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1820977.5 | 2018-12-21 | ||
| GBGB1820977.5A GB201820977D0 (en) | 2018-12-21 | 2018-12-21 | Fixaxfx bispecific antibody with commomn light chain |
| GBGB1906816.2A GB201906816D0 (en) | 2019-05-15 | 2019-05-15 | FIXaxFX bispecific antibody with common light chain |
| GB1906816.2 | 2019-05-15 | ||
| GB1908190.0 | 2019-06-07 | ||
| GBGB1908190.0A GB201908190D0 (en) | 2019-06-07 | 2019-06-07 | Fixaxfx bispecific antibody with common light chain |
| PCT/EP2019/086808 WO2020128049A1 (en) | 2018-12-21 | 2019-12-20 | Fixaxfx bispecific antibody with common light chain |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022515770A JP2022515770A (ja) | 2022-02-22 |
| JP2022515770A5 true JP2022515770A5 (https=) | 2022-12-28 |
| JP7530362B2 JP7530362B2 (ja) | 2024-08-07 |
Family
ID=69167786
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021535950A Active JP7530362B2 (ja) | 2018-12-21 | 2019-12-20 | 共通の軽鎖を有するＦＩＸａ×ＦＸ二重特異性抗体 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US10815308B2 (https=) |
| EP (2) | EP4015538A1 (https=) |
| JP (1) | JP7530362B2 (https=) |
| KR (1) | KR20210118085A (https=) |
| CN (1) | CN113453757B (https=) |
| BR (1) | BR112021012065A2 (https=) |
| CA (1) | CA3123177A1 (https=) |
| DK (1) | DK3723858T3 (https=) |
| ES (1) | ES2901683T3 (https=) |
| HR (1) | HRP20220088T1 (https=) |
| HU (1) | HUE057634T2 (https=) |
| LT (1) | LT3723858T (https=) |
| PL (1) | PL3723858T3 (https=) |
| PT (1) | PT3723858T (https=) |
| RS (1) | RS62848B1 (https=) |
| SI (1) | SI3723858T1 (https=) |
| TW (1) | TWI772724B (https=) |
| WO (1) | WO2020128049A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201709970D0 (en) | 2017-06-22 | 2017-08-09 | Kymab Ltd | Bispecific antigen-binding molecules |
| US10815308B2 (en) | 2018-12-21 | 2020-10-27 | Kymab Limited | FIXaxFX bispecific antibody with common light chain |
| CN113939541A (zh) * | 2019-05-15 | 2022-01-14 | 科马布有限公司 | 改进的λ抗体 |
| GB2590642B (en) * | 2019-12-20 | 2024-02-14 | Kymab Ltd | Improved lambda antibodies |
| CN115728433B (zh) * | 2021-08-27 | 2024-11-15 | 联邦生物科技(珠海横琴)有限公司 | IgG4型单克隆抗体电荷异质性的离子交换色谱检测方法 |
| WO2023111018A1 (en) * | 2021-12-17 | 2023-06-22 | F. Hoffmann-La Roche Ag | Antibodies against coagulation factor x and uses thereof |
| EP4473008A4 (en) * | 2022-01-31 | 2025-12-31 | Childrens Hospital Philadelphia | COMPOSITIONS AND METHODS OF TREATMENT OF A FACTOR IX DEFICIENCY |
| US12098400B2 (en) | 2022-07-08 | 2024-09-24 | Novo Nordisk A/S | Highly potent ISVD compounds capable of substituting for FVIII(A) |
| GB202319967D0 (en) | 2023-12-22 | 2024-02-07 | Epsilogen Ltd | Heteromultimeric proteins |
| WO2026036047A1 (en) * | 2024-08-08 | 2026-02-12 | Altus Enterprises, Inc. | Antibody molecules to fixa and fx and uses thereof |
| WO2026037918A1 (en) | 2024-08-14 | 2026-02-19 | Epsilogen Ltd | Heteromultimeric proteins |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6749853B1 (en) | 1992-03-05 | 2004-06-15 | Board Of Regents, The University Of Texas System | Combined methods and compositions for coagulation and tumor treatment |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| MA24512A1 (fr) | 1996-01-17 | 1998-12-31 | Univ Vermont And State Agrienl | Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose |
| ATE299938T1 (de) | 1997-05-02 | 2005-08-15 | Genentech Inc | Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen |
| AT411997B (de) | 1999-09-14 | 2004-08-26 | Baxter Ag | Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate |
| US7083784B2 (en) | 2000-12-12 | 2006-08-01 | Medimmune, Inc. | Molecules with extended half-lives, compositions and uses thereof |
| US7297336B2 (en) * | 2003-09-12 | 2007-11-20 | Baxter International Inc. | Factor IXa specific antibodies displaying factor VIIIa like activity |
| WO2005035753A1 (ja) | 2003-10-10 | 2005-04-21 | Chugai Seiyaku Kabushiki Kaisha | 機能蛋白質を代替する二重特異性抗体 |
| AU2003271186A1 (en) | 2003-10-14 | 2005-04-27 | Chugai Seiyaku Kabushiki Kaisha | Double specific antibodies substituting for functional protein |
| AU2006232287B2 (en) | 2005-03-31 | 2011-10-06 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
| PT1876236E (pt) | 2005-04-08 | 2014-10-22 | Chugai Pharmaceutical Co Ltd | Anticorpos para substituição da função do factor de coagulação sanguínea viii |
| HRP20120851T1 (hr) | 2005-07-05 | 2012-11-30 | Glaxo Group Limited | Humanizirana protutijela specifiäśna za nogo-a i njihova farmaceutska upotreba |
| PT1999154E (pt) | 2006-03-24 | 2013-01-24 | Merck Patent Gmbh | Domínios proteicos heterodiméricos modificados |
| WO2007120767A2 (en) * | 2006-04-14 | 2007-10-25 | Amgen Inc. | Agonist erythropoietin receptor antibodies |
| MY192182A (en) | 2009-06-26 | 2022-08-04 | Regeneron Pharma | Readily isolated bispecific antibodies with native immunoglobulin format |
| CA2785414C (en) * | 2009-12-25 | 2019-01-22 | Tomoyuki Igawa | Polypeptide modification method for purifying polypeptide multimers |
| US9527926B2 (en) | 2010-05-14 | 2016-12-27 | Rinat Neuroscience Corp. | Heterodimeric proteins and methods for producing and purifying them |
| TWI452136B (zh) * | 2010-11-17 | 2014-09-11 | 中外製藥股份有限公司 | A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation |
| US20140356377A1 (en) | 2011-08-25 | 2014-12-04 | Umc Utrecht Holding B.V. | Compounds for use in boosting coagulation |
| US9248181B2 (en) | 2012-04-20 | 2016-02-02 | Merus B.V. | Methods and means for the production of Ig-like molecules |
| CN104854133B (zh) | 2012-10-12 | 2018-10-30 | 新加坡科技研究局 | 用于制备重组抗体治疗剂的最佳重链和轻链信号肽 |
| WO2014177459A2 (en) * | 2013-04-29 | 2014-11-06 | F. Hoffmann-La Roche Ag | Fc-receptor binding modified asymmetric antibodies and methods of use |
| CN105848668A (zh) | 2013-11-04 | 2016-08-10 | 加利福尼亚大学董事会 | 治疗或预防与出血或低凝血相关联的病状的疗法 |
| US10519251B2 (en) | 2013-12-30 | 2019-12-31 | Epimab Biotherapeutics, Inc. | Fabs-in-tandem immunoglobulin and uses thereof |
| TWI831106B (zh) | 2014-06-20 | 2024-02-01 | 日商中外製藥股份有限公司 | 用於因第viii凝血因子及/或活化的第viii凝血因子的活性降低或欠缺而發病及/或進展的疾病之預防及/或治療之醫藥組成物 |
| TWI700300B (zh) | 2014-09-26 | 2020-08-01 | 日商中外製藥股份有限公司 | 中和具有第ｖｉｉｉ凝血因子（ｆｖｉｉｉ）機能替代活性的物質之抗體 |
| JP6698102B2 (ja) | 2015-04-17 | 2020-05-27 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 凝固因子と多重特異的抗体を用いた併用療法 |
| JP2018123055A (ja) | 2015-04-24 | 2018-08-09 | 公立大学法人奈良県立医科大学 | 血液凝固第ｖｉｉｉ因子（ｆｖｉｉｉ）の機能を代替する多重特異性抗原結合分子を含有する、血液凝固第ｘｉ因子（ｆｘｉ）異常症の予防および／または治療に用いられる医薬組成物 |
| WO2016207402A1 (en) * | 2015-06-26 | 2016-12-29 | Institute For Research In Biomedicine | Proteins comprising a mutated lair-1 fragment and uses thereof |
| EP3368561B1 (en) | 2015-10-30 | 2025-09-17 | Medimmune Limited | Prevention of n-terminal truncation in igg light chains |
| WO2017110980A1 (ja) | 2015-12-25 | 2017-06-29 | 中外製薬株式会社 | 増強された活性を有する抗体及びその改変方法 |
| WO2017132827A1 (en) * | 2016-02-02 | 2017-08-10 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| US11421028B2 (en) | 2016-02-06 | 2022-08-23 | Epimab Biotherapeutics, Inc. | Fabs-in-tandem immunoglobulin and uses thereof |
| KR102625416B1 (ko) | 2016-05-16 | 2024-01-15 | 다케다 파머수티컬 컴패니 리미티드 | 항-인자 ix 파두아 항체 |
| US20190185578A1 (en) * | 2016-07-29 | 2019-06-20 | Chugai Seiyaku Kabushiki Kaisha | Bispecific antibody exhibiting increased alternative fviii-cofactor-function activity |
| PL3509637T3 (pl) | 2016-09-06 | 2025-03-10 | Chugai Seiyaku Kabushiki Kaisha | Sposoby zastosowania dwuswoistego przeciwciała, które rozpoznaje czynnik krzepnięcia IX i/lub aktywowany czynnik krzepnięcia IX oraz czynnik krzepnięcia X i/lub aktywowany czynnik krzepnięcia X |
| TN2019000164A1 (en) * | 2016-11-23 | 2020-10-05 | Bioverativ Therapeutics Inc | Mono- and bispecific antibodies binding to coagulation factor ix and coagulation factor x |
| EP3577140A1 (en) | 2017-02-01 | 2019-12-11 | Novo Nordisk A/S | Procoagulant antibodies |
| WO2018145125A1 (en) | 2017-02-06 | 2018-08-09 | Applied Stemcell, Inc. | Coagulation factor viii mimetic protein and uses thereof |
| EP3615574A4 (en) * | 2017-04-26 | 2021-02-24 | Eureka Therapeutics, Inc. | SPECIFIC GLYPICAN 3 RECOGNIZING CONSTRUCTS AND THEIR USE |
| WO2018209265A1 (en) | 2017-05-11 | 2018-11-15 | Atreca, Inc. | Anti-malarial antibodies that bind circumsporozoite protein |
| GB201709970D0 (en) * | 2017-06-22 | 2017-08-09 | Kymab Ltd | Bispecific antigen-binding molecules |
| PE20210005A1 (es) | 2017-09-29 | 2021-01-05 | Chugai Pharmaceutical Co Ltd | Molecula de union al antigeno multiespecifica que tiene actividad de sustitucion de la funcion de cofactor del factor viii de coagulacion de sangre (fviii) y formulacion farmaceutica que contiene tal molecula como ingrediente activo |
| JP7841846B2 (ja) | 2017-11-15 | 2026-04-07 | ノヴォ ノルディスク アー／エス | Ｆｘ活性化を促進する第ｘ因子結合剤 |
| US10815308B2 (en) * | 2018-12-21 | 2020-10-27 | Kymab Limited | FIXaxFX bispecific antibody with common light chain |
-
2019
- 2019-12-20 US US16/722,452 patent/US10815308B2/en active Active
- 2019-12-20 EP EP21204339.2A patent/EP4015538A1/en active Pending
- 2019-12-20 JP JP2021535950A patent/JP7530362B2/ja active Active
- 2019-12-20 US US17/311,595 patent/US20220064327A1/en not_active Abandoned
- 2019-12-20 RS RS20220069A patent/RS62848B1/sr unknown
- 2019-12-20 HU HUE19836806A patent/HUE057634T2/hu unknown
- 2019-12-20 CA CA3123177A patent/CA3123177A1/en active Pending
- 2019-12-20 DK DK19836806.0T patent/DK3723858T3/da active
- 2019-12-20 ES ES19836806T patent/ES2901683T3/es active Active
- 2019-12-20 BR BR112021012065A patent/BR112021012065A2/pt not_active Application Discontinuation
- 2019-12-20 PT PT198368060T patent/PT3723858T/pt unknown
- 2019-12-20 TW TW108146911A patent/TWI772724B/zh active
- 2019-12-20 HR HRP20220088TT patent/HRP20220088T1/hr unknown
- 2019-12-20 PL PL19836806T patent/PL3723858T3/pl unknown
- 2019-12-20 WO PCT/EP2019/086808 patent/WO2020128049A1/en not_active Ceased
- 2019-12-20 EP EP19836806.0A patent/EP3723858B1/en active Active
- 2019-12-20 SI SI201930150T patent/SI3723858T1/sl unknown
- 2019-12-20 KR KR1020217022770A patent/KR20210118085A/ko not_active Ceased
- 2019-12-20 LT LTEPPCT/EP2019/086808T patent/LT3723858T/lt unknown
- 2019-12-20 CN CN201980091786.3A patent/CN113453757B/zh active Active
-
2020
- 2020-10-06 US US17/063,905 patent/US11976135B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022515770A5 (https=) | ||
| US10723786B2 (en) | RSV-specific binding molecule | |
| Milo | Therapies for multiple sclerosis targeting B cells | |
| TWI890481B (zh) | 雙特異性抗體 | |
| KR102171669B1 (ko) | 조합물 및 이의 용도 | |
| JP2025134874A (ja) | ブラジキニンｂ１受容体リガンドに対する抗体 | |
| JP2017507954A5 (https=) | ||
| JP2023548858A5 (https=) | ||
| JP2017536354A5 (https=) | ||
| CN106794244A (zh) | 用于降低心血管风险的方法 | |
| JP2024520666A5 (https=) | ||
| JP2024531151A5 (https=) | ||
| CN103864932A (zh) | 拮抗抑制血管内皮细胞生长因子与其受体结合的单克隆抗体及其编码序列与用途 | |
| KR20180008571A (ko) | 다발성 골수종(mm)의 치료 | |
| CN1311691A (zh) | 抗凝剂和人源化抗冯·维勒布兰德氏因子的单克隆抗体 | |
| JP2024540226A5 (https=) | ||
| WO2015028888A2 (en) | Pharmaceutical compositions to treat viral infection | |
| JP2022544050A5 (https=) | ||
| JP2024511853A5 (https=) | ||
| JP2022534494A5 (https=) | ||
| JP2023531722A5 (https=) | ||
| JP2013542188A (ja) | 治療用第ｖｉｉｉ因子抗体 | |
| US20230406942A1 (en) | Igf1r antibodies | |
| JP2022527542A5 (https=) | ||
| US20240207277A1 (en) | Methods For Treating Drug and Vaccine Induced Immune Thrombocytopenia by Administering Specific Compounds |